Confronting the scientific obstacles to global control of tuberculosis

被引:277
作者
Young, Douglas B. [2 ]
Perkins, Mark D. [3 ]
Duncan, Ken [1 ]
Barry, Clifton E., III [4 ]
机构
[1] Bill & Melinda Gares Fdn, Seattle, WA 98102 USA
[2] Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Med, London, England
[3] FIND, Cointrin, Switzerland
[4] TB Res Sect, Bethesda, MD USA
基金
英国医学研究理事会;
关键词
D O I
10.1172/JCI34614
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Tuberculosis (TB) is a major threat to global health, recently exacerbated by the emergence of highly drug-resistant forms of the disease-causing pathogen and synergy with HIV/AIDS. In 2006, the Stop TB Partnership published "The global plan to stop TB: 2006-2015," which set out a vision of halving the prevalence of and mortality caused by the disease by 2015, followed by eliminating the disease as a public health problem by 2050. This vision depends on the development of improved diagnostics, simpler treatment, and more effective vaccination. Recently; active translational research pipelines directed toward each of these goals have been established, but improved understanding of the fundamental biology of this complex disease will prove to be the key to radical advances in TB control.
引用
收藏
页码:1255 / 1265
页数:11
相关论文
共 141 条
[1]   Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31 [J].
Agger, Else Marie ;
Rosenkrands, Ida ;
Olsen, Anja Weinreich ;
Hatch, Graham ;
Williams, Ann ;
Kritsch, Constantia ;
Lingnau, Karen ;
von Gabain, Alexander ;
Andersen, Claire Swetman ;
Korsholm, Karen Smith ;
Andersen, Peter .
VACCINE, 2006, 24 (26) :5452-5460
[2]   Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum [J].
Agranoff, Dan ;
Fernandez-Reyes, Delmiro ;
Papadopoulos, Marios C. ;
Rojas, Sergio A. ;
Herbster, Mark ;
Loosemore, Alison ;
Tarelli, Edward ;
Sheldon, Jo ;
Schwenk, Achim ;
Pollak, Richard ;
Rayner, Charlotte F. J. ;
Krishna, Sarjeev .
LANCET, 2006, 368 (9540) :1012-1021
[3]   In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis [J].
Alvirez-Freites, EJ ;
Carter, JL ;
Cynamon, MH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (04) :1022-1025
[4]   A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis [J].
Andries, K ;
Verhasselt, P ;
Guillemont, J ;
Göhlmann, HWH ;
Neefs, JM ;
Winkler, H ;
Van Gestel, J ;
Timmerman, P ;
Zhu, M ;
Lee, E ;
Williams, P ;
de Chaffoy, D ;
Huitric, E ;
Hoffner, S ;
Cambau, E ;
Truffot-Pernot, C ;
Lounis, N ;
Jarlier, V .
SCIENCE, 2005, 307 (5707) :223-227
[5]  
[Anonymous], 2007, GLOBAL TUBERCULOSIS
[6]  
[Anonymous], 1891, Dtsch Med Wschr, DOI [10.1055/s-0029-1206198, DOI 10.1055/S-0029-1206198]
[7]  
[Anonymous], 2004, The World Health Report 2004
[8]  
Anthony RM, 2006, INT J TUBERC LUNG D, V10, P1060
[9]  
Arora S., 2004, 44 INT C ANT AG CHEM
[10]  
Balganesh T. S., 2007, Infectious Disorders - Drug Targets, V7, P120